Publikationen

Artikel in internationalen Fachjournalen

The value of indocyanine green clearance assessment to predict postoperative liver dysfunction in patients undergoing liver resection
Schwarz C, Plass I, Fitschek F, Punzengruber A, Mittlböck M, Kampf S, Asenbaum U, Starlinger P, Stremitzer S, Bodingbauer M, Kaczirek K.
Sci Rep. 2019 Jun 10;9(1):8421.

Defining enhanced recovery after resection of peri-hilar cholangiocarcinoma
Quinn LM, Mann K, Jones RP, Bathla S, Stremitzer S, Dunne DF, Lacasia C, Fenwick SW, Malik HZ.
Eur J Surg Oncol. 2019 Aug;45(8):1439-1445.

Clinical outcome after resection of early-stage cholangiocarcinoma
Stremitzer S, Jones RP, Quinn LM, Fenwick SW, Diaz-Nieto R, Poston GJ, Malik HZ.
Eur J Surg Oncol. 2019 Feb;45(2):213-217.

Circulating Free Methylated Tumor DNA Markers for Sensitive Assessment of Tumor Burden and Early Response Monitoring in Patients Receiving Systemic Chemotherapy for Colorectal Cancer Liver Metastasis
Bhangu JS, Beer A, Mittlböck M, Tamandl D, Pulverer W, Taghizadeh H, Stremitzer S, Kaczirek K, Gruenberger T, Gnant M, Bergmann M, Mannhalter C, Weinhäusel A, Oehler R, Bachleitner-Hofmann T.
Ann Surg. 2018 Nov;268(5):894-902.

DNA damage predicts prognosis and treatment response in colorectal liver metastases superior to immunogenic cell death and T cells
Laengle J, Stift J, Bilecz A, Wolf B, Beer A, Hegedus B, Stremitzer S, Starlinger P, Tamandl D, Pils D, Bergmann M.
Theranostics. 2018 May 10;8(12):3198-3213.

Microscopic biliary and perineural invasion and clinical outcome after neoadjuvant bevacizumab-based chemotherapy and liver resection in patients with colorectal liver metastases
Stift J, Graf A, Schwarz C, Tamandl D, Starlinger P, Herac M, Beer A, Wrba F, Bodingbauer M, Kaczirek K, Stremitzer S.
Eur J Surg Oncol. 2018 Jan;44(1):139-147.

Prognostic impact of FOXF1 polymorphisms in gastric cancer patients
Matsusaka S, Wu AH, Cao S, Hanna DL, Chin K, Yang D, Zhang W, Ning Y, Stintzing S, Sebio A, Sunakawa Y, Stremitzer S, Yamauchi S, Okazaki S, Berger MD, Parekh A, Miyamoto Y, Mizunama N, Lenz HJ.
Pharmacogenomics J. 2018 Apr;18(2):262-269.

Perioperative non-invasive indocyanine green-clearance testing to predict postoperative outcome after liver resection
Haegele S, Reiter S, Wanek D, Offensperger F, Pereyra D, Stremitzer S, Fleischmann E, Brostjan C, Gruenberger T, Starlinger P.
PLoS One. 2016 Nov 3;11(11):e0165481.

Expression of genes involved in vascular morphogenesis and maturation predicts efficacy of bevacizumab-based chemotherapy in patients undergoing liver resection
Stremitzer S, Zhang W, Yang D, Ning Y, Sunakawa Y, Matsusaka S, Parekh A, Okazaki S, Hanna D, Astrow SH, Moran M, Hernandez J, Stephens C, Scherer SJ, Stift J, Wrba F, Gruenberger T, Lenz HJ.
Mol Cancer Ther. 2016 Nov;15(11):2814-2821.

A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials
Sebio A, Stintzing S, Heinemann V, Sunakawa Y, Zhang W, Ichikawa W, Tsuji A, Takahashi T, Parek A, Yang D, Cao S, Ning Y, Stremitzer S, Matsusaka S, Okazaki S, Barzi A, Berger MD, Lenz HJ.
Pharmacogenomics J. 2018 Jan;18(1):43-48.

PARAGON II – A single arm multicentre phase II study of neoadjuvant therapy using irinotecan bead in patients with resectable liver metastases from colorectal cancer
Jones RP, Malik HZ, Fenwick SW, Terlizzo M, O’Grady E, Stremitzer S, Gruenberger T, Rees M, Plant G, Figueras J, Albiol M, Adam R, Awad S, Poston GJ.
Eur J Surg Oncol. 2016 Dec;42(12):1866-1872.

CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy Matsusaka S, Cao S, Hanna DL, Sunakawa Y, Ueno M, Mizunuma N, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Stremitzer S, Yamauchi S, Parekh A, Okazaki S, Berger MD, El-Khoueiry R, Mendez A, Ichikawa, Loupakis F, Lenz HJ.
Pharmacogenomics J. 2017 Dec;17(6):543-550.

Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer
Sunakawa Y, Cao S, Volz NB, Berger MD, Yang D, Parekh A, Zhang W, Matsusaka S, Ning Y, Stremitzer S, Stintzing S, Sebio A, Okazaki S, Wakatsuki T, Azuma M, Watanabe M, Koizumi W, Wu AH, Lenz HJ.
Pharmacogenomics J. 2017 Dec;17(6):528-534.

Clinical significance of TLR1 I602S piolymorphism for patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab
Okazaki S, Loupakis F, Stintzing S, Cao S, Zhang W, Yang D, Ning Y, Sunakawa Y, Stremitzer S, Matsusaka S, Berger MD, Parekh A, West JD, Miyamoto Y, Suenaga M, Schirripa M, Cremolini C, Falcone A, Heinemann V, DePaolo RW, Lenz HJ.
Mol Cancer Ther. 2016 Jul;15(7):1740-5.

Genetic variants associated with colorectal brain metastases susceptibility and survival
Stremitzer S, Berghoff AS, Volz NB, Zhang W, Yang D, Stintzing S, Ning Y, Sunakawa Y, Yamauchi S, Sebio A, Matsusaka S, Okazaki S, Hanna D, Parekh A, Mendez A, Berger MD, El-Khoueiry R, Birner P, Preusser M, Lenz HJ.
Pharmacogenomics J. 2017 Jan;17(1):29-35.

Estrogen receptor-beta genetic variations and overall survival in patients with locally advanced gastric cancer
Sunakawa Y, Cao S, Berger MD, Matsusaka S, Yang D, Zhang W, Ning Y, Parekh A, Stremitzer S, Mendez A, Okazaki S, Wakatsuki T, Azuma M, Shimada K, Watanabe M, Koizumi W, Wu AH, Lenz HJ.
Pharmacogenomics J. 2017 Jan;17(1):36-41.

Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: results from TRIBE and FIRE3 trials
Sunakawa Y, Stintzing S, Cao S, Heinemann V, Cremolini C, Falcone A, Yang D, Zhang W, Ning Y, Stremitzer S, Matsusaka S, Yamauchi S, Parekh A, Okazaki S, Berger MD, Graver S, Mendez A, Scherer SJ, Loupakis F, Lenz HJ.
Ann Oncol. 2015 Dec;26(12):2450-6.

Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer.
Sebio A, Matsusaka S, Zhang W, Yang D, Ning Y, Stremitzer S, Stintzing S, Sunakawa Y, Yamauchi S, Fujimoto Y, Ueno M, Lenz HJ.
Pharmacogenomics J. 2016 Aug; 16(4):312-9.

Cytokeratin-20 and survivin-expressing circulating tumor cells predict survival in metastatic colorectal cancer patients by a combined immunomagnetic qRT-PCR approach
Ning Y, Hanna DL, Zhang W, Mendez A, Yang D, El-Khoueiry R, Matsusaka S, Sunakawa Y, Stremitzer S, Parekh A, Okazaki S, Berger MD, Barzi A, Lenz HJ.
Mol Cancer Ther. 2015 Oct; 14(10):2401-8.

Polymorphisms in genes involved in EGFR-turnover are predictive for cetuximab efficacy in colorectal cancer
Stintzing S, Zhang W, Heinemann V, Neureiter D, Kemmerling R, Kirchner T, Jung A, Folwaczny M, Yang D, Ning Y, Sebio A, Stremitzer S, Sunakawa Y, Matsusaka S, Yamauchi S, Loupakis F, Cremolini C, Falcone A, Lenz HJ.
Mol Cancer Ther. 2015 Oct; 14(10):2374-81.

Variations in genes involved in dormancy associated with outcome in patients with resected colorectal liver metastases
Stremitzer S, Zhang W, Yang D, Ning Y, Stintzing S, Sunakawa Y, Sebio A, Yamauchi S, Matsusaka S, Parekh A, Barzi A, El-Khoueiry R, Stift J, Wrba F, Gruenberger T, Lenz HJ.
Ann Oncol. 2015 Aug;26(8):1728-33.

Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases
Stremitzer S, Stift J, Singh J, Starlinger P, Gruenberger B, Tamandl D, Gruenberger T.
Eur J Surg Oncol. 2015 Jul;41(7):868-74.

Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases
Stremitzer S, Sunakawa Y, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Yamauchi S, Matsusaka S, El-Khoueiry R, Stift J, Wrba F, Gruenberger T, Lenz HJ.
Pharmacogenomics J. 2015 Dec; 15(6):521-9.

Association of variants in genes encoding for macrophage-related functions with clinical outcome in patients with loco-regional gastric cancer
Sunakawa Y, Stremitzer S, Cao S, Zhang W, Yang D, Wakatsuki T, Ning Y, Yamauchi S, Stintzing S, Sebio A, El-Khoueiry R, Matsusaka S, Parekh A, Barzi A, Azuma M, Watanabe M, Koizumi W, Lenz HJ.
Ann Oncol. 2015 Feb;26(2)332-9.

Genetic variants within obesity-related genes are associated with tumor recurrence in patients with stages II/III colon cancer
Sebio A, Gerger A, Matsusaka S, Yang D, Zhang W, Stremitzer S, Stintzing S, Sunakawa Y, Yamauchi S, Ning Y, Fujimoto Y, Ueno M, Lenz HJ.
Pharmacogenet Genomics. 2015 Jan;25(1)30-7.

CEA change after neoadjuvant chemotherapy including bevacizumab and clinical outcome in patients undergoing liver resection for colorectal liver metastases
Stremitzer S, Stift J, Graf A, Singh J, Starlinger P, Gruenberger B, Tamandl D, Gruenberger T.
Ann Surg Oncol. 2015 Apr;22(4):1315-23.

Genetic variations in angiopoietin and pericyte pathways and clinical outcome in patients with resected colorectal liver metastases
Stremitzer S, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Sunakawa Y, Yamauchi S, Matsusaka S, El-Khoueiry R, Stift J, Wrba F, Gruenberger T, Lenz HJ.
Cancer. 2015 Jun 1;121(11):1898-905.

Prognostic impact of the c-MET polymorphism on the clinical outcome in locoregional gastric cancer patients
Sunakawa Y, Wakatsuki T, Yang D, Zhang W, Ning Y, Stintzing S, Stremitzer S, Yamauchi S, Sebio A, El-Khoueiry R, Iqbal S, Barzi A, Gerger A, Stotz M, Azuma M, Watanabe M, Koizumi W, Lenz HJ.
Pharmacogenet Genomics. 2014 Dec;24(12):588-96

B cells and ectopic follicular structures: novel players in anti-tumor programming with prognostic power for patients with metastatic colorectal cancer
Meshcheryakova A, Tamandl D, Bajna E, Stift J, Mittlboeck M, Svoboda M, Heiden D, Stremitzer S, Jensen-Jarolim E, Grünberger T, Bergmann M, Mechtcheriakova D.
PLoS One. 2014 Jun 6;9(6):e99008.

Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy
Ning Y, Gerger A, Zhang W, Hanna DL, Yang D, Winder T, Wakatsuki T, Labonte MJ, Stintzing S, Volz N, Sunakawa Y, Stremitzer S, El-Khoueiry R, Lenz HJ.
Mol Cancer Ther. 2014 Feb;13(2):528-39.

Multicenter Validation Study of Pathologic Response and Tumor Thickness at the Tumor–Normal Liver Interface as Independent Predictors of Disease-Free Survival after Preoperative Chemotherapy and Surgery for Colorectal Liver Metastases
Brouquet A, Zimmitti G, Kopetz S, Stift J, Julié C, Lemaistre AI, Agarwal A, Benoist S, Nordlinger B, Rivoire M, Stremitzer S, Gruenberger T, Vauthey JM, Maru D
Cancer. 2013 Aug 1;119(15):2778-88.

Segmental and lobar administration of drug-eluting beads delivering irinotecan leads to tumour destruction-a case-control series
Jones RP, Dunne D, Sutton P, Malik HZ, Fenwick SW, Terlizzo M, O’Grady E, Koelblinger C, Staettner S, Stremitzer S, Gruenberger T, Poston GJ
HPB (Oxford). 2013 Jan;15(1):71-77.

KRAS status and outcome of liver resection after neoadjuvant chemotherapy including Bevacizumab
Stremitzer S, Stift J, Gruenberger B, Tamandl D, Aschacher T, Wolf B, Wrba F, Gruenberger T
Br J Surg. 2012 Nov;99(11):1575-82.

Repeat endorectal advancement flap after flap breakdown and recurrence of fistula-in-ano. Is it an option?
Stremitzer S, Riss S, Swoboda P, Dauser B, Dubsky P, Birsan T, Herbst F, Stift A
Colorectal Dis. 2012 Nov;14(11):1389-93.

Value of hepatic venous pressure gradient measurement before liver resection for hepatocellular carcinoma
Stremitzer S, Tamandl D, Kaczirek K, Maresch J, Abbasov B, Payer BA, Ferlitsch A, Gruenberger T
Br J Surg. 2011 Dec;98(12):1752-8.

Successful bridging treatment and healing of enteric fistulae by vacuum-assisted closure (VAC) therapy and targeted drainage in patients with open abdomen
Stremitzer S, Dal Borgo A, Wild T, Goetzinger P
Int J Colorectal Dis. 2011 May;26(5):661-6.

Pelvic organ function and quality of life after after anastomotic leakage following rectal cancer surgery
Riss S, Stremitzer S, Riss K, Mittlböck M, Bergmann M, Stift A
Wien Klin Wochenschr. 2011 Jan;123(1-2):53-7.

Endogenous expression of proteases in colon cancer cells facilitate influenza A viruses mediated oncolysis
Sturlan S, Stremitzer S, Bauman S, Sachet M, Wolschek M, Ruthsatz T, Egorov A, Bergmann M
Cancer Biol Ther. 2010 Sep;10(6):592-9.

Mesh graft infection following abdominal hernia repair: risk factor evaluation and strategies of mesh graft preservation. A retrospective analysis of 476 operations
Stremitzer S, Bachleitner-Hofmann T, Gradl B, Gruenbeck M, Bachleitner-Hofmann B, Mittlboeck M, Bergmann M
World J Surg. 2010 Jul;34(7):1702-9.

Treatment of perianal sepsis and long-term outcome of recurrence and continence
Stremitzer S, Strobl S, Kure V, Birsan T, Puhalla H, Herbst F, Stift A
Colorectal Dis. 2011 Jun;13(6):703-7.

Definition of efficiency in vacuum therapy – a randomized controlled trial comparing with V.A.C. – Therapy
Wild T, Stremitzer S, Budzanowski A, Hoelzenbein T, Ludwig C, Ohrenberger G
Int Wound J. 2008 Dec;5(5):641-7.

How precise is the evaluation of chronic wounds by health care professionals?
Stremitzer S, Wild T, Hölzenbein T.
Int Wound J. 2007 Jun;4(2):156-61.

Abdominal dressing - a new standard in therapy of the open abdomen following secondary peritonitis?
Wild T, Stortecky S, Stremitzer S, Lechner P, Humpel G, Glaser K, Fortelny R, Karner J, Sautner T.
Zentralbl Chir. 2006 Apr;131 Suppl 1:111-4.

"Abdominal dressing" - a new method of treatment for open abdomen following secondary peritonitis
Wild T, Stremitzer S, Budzanowski A, Rinder H, Tamandl D, Zeisel C, Holzenbein T, Sautner T.
Zentralbl Chir. 2004 May;129 Suppl 1:20-3.

Long-term follow-up of surgically treated gallbladder cancer patients
Puhalla H, Wild T, Bareck E, Pokorny H, Ploner M, Soliman T, Stremitzer S, Depisch D, Laengle F, Gruenberger T.
Eur J Surg Oncol. 2002 Dec;28(8):857-63.

Dissertation

Automatische Nahtvorlage beim Setzen endoskopischer Trokare
Stremitzer S., Betreuer: Univ.Prof. Dr. Georg Bischof, Univ. Prof. DI. Dr. Winfried Mayr
Universitätsbibliothek, Medizinische Universität Wien